Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Kimelman & Baird LLC

Kimelman & Baird LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 154.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,671 shares of the biopharmaceutical company’s stock after acquiring an additional 16,815 shares during the quarter. Kimelman & Baird LLC’s holdings in Regeneron Pharmaceuticals were worth $17,254,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $26,000. Western Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $29,000. Finally, Trust Co. of Vermont purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $29,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares in the company, valued at $482,400. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock valued at $1,090,030 over the last 90 days. 6.97% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on REGN. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. HSBC decreased their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Finally, Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Fifteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $800.36.

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of NASDAQ:REGN opened at $794.19 on Friday. The stock has a market capitalization of $81.77 billion, a PE ratio of 19.63, a P/E/G ratio of 1.37 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $847.00. The firm has a fifty day moving average price of $717.52 and a 200 day moving average price of $718.38. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $12.81 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.